Factors Influencing Quality of Life in Breast Cancer Patients Six Months after the Completion of Chemotherapy

Maria Lavdaniti, Dimitra Anna Owens, Polixeni Liamopoulou, Kalliopi Marmara, Efrosini Zioga, Michael S Mantzanas, Eftychia Evangelidou, Eugenia Vlachou, Maria Lavdaniti, Dimitra Anna Owens, Polixeni Liamopoulou, Kalliopi Marmara, Efrosini Zioga, Michael S Mantzanas, Eftychia Evangelidou, Eugenia Vlachou

Abstract

Purpose: To assess breast cancer patients' quality of life six months after the completion of adjuvant chemotherapy, and to investigate factors affecting this.

Methods: The study was conducted in one large hospital located in a major Greek city. A convenience sample of 61 breast cancer outpatients was recruited. A questionnaire, including the SF-36 scale and questions regarding demographic and clinical information, was used to collect data.

Results: The mean age of the patients was 51.52 ± 12.10. The effect of age on the physical role was significant (p = 0.003). Τhe effect of menopausal status on physical role was also found to be significant (p = 0.003); this might be explained by age. Regarding the treatment type, patients who received hormone therapy in addition to surgery and chemotherapy reported a significantly higher quality of life in terms of bodily pain (p = 0.04) and vitality (p = 0.04) than patients who underwent only surgery and chemotherapy.

Conclusions: Quality of life is affected by factors such as age, menopausal status, and previous therapy. Health care professionals should be more aware of the factors that influence the quality of life domains (physical role, bodily pain, vitality) within this group of cancer patients in order to meet their needs following acute treatment.

Keywords: breast cancer; chemotherapy; quality of life.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) Mean bodily pain scores according to treatment type across the surgery groups. Error bars show the standard error of the mean; (b) mean vitality scores according to treatment type across the surgery groups. Error bars show the standard error of the mean.

References

    1. National Plan for Breast Cancer 2011–2015. [(accessed on 24 July 2018)]; Available online:
    1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer. 2013;49:1374–1403. doi: 10.1016/j.ejca.2012.12.027.
    1. Van der Steeg A.F., De Vries J., Roukema J.A. Quality of life and health status in breast carcinoma. Eur. J. Surg. Oncol. 2004;30:1051–1057. doi: 10.1016/j.ejso.2004.07.003.
    1. Groenvold M. Health-related quality of life in early breast cancer. Dan. Med. Bull. 2010;57:B4184.
    1. Montazeri A. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J. Exp. Clin. Cancer Res. 2008;27:32. doi: 10.1186/1756-9966-27-32.
    1. Dialla P.O., Chu W.O., Roignot P., Bone-Lepinoy M.C., Poillot M.L., Coutant C., Arveux P., Dabakuyo-Yonli T.S. Impact of age-related socioeconomic and clinical determinants of quality of life among long-term breast cancer survivors. Maturitas. 2015;81:362–370. doi: 10.1016/j.maturitas.2015.03.025.
    1. Yeo W., Mo F.K., Pang E., Suen J.J., Koh J., Yip C.H., Yip C.C., Li L., Loong H.H., Liem G.S. Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy. Cancer Manag. Res. 2018;10:383–389. doi: 10.2147/CMAR.S149983.
    1. Chu W.O., Dialla P.O., Roignot P., Bone-Lepinoy M.C., Poillot M.L., Coutant C., Arveux P., Dabakuyo-Yonli T.S. Determinants of quality of life among long-term breast cancer survivors. Qual. Life Res. 2016;25:1981–1990. doi: 10.1007/s11136-016-1248-z.
    1. Daldoul A., Khechine W., Bhiri H., Ammar N., Bouriga R., Krir M.W., Soltani S., Zoukar O., Rhim M.S., Bouslah S., et al. Factors Predictive of Quality of Life among Breast Cancer Patients. Asian Pac. J. Cancer Prev. 2018;19:1671–1675.
    1. Tsai H.Y., Kuo R.N., Chung K.P. Quality of life of breast cancer survivors following breast-conserving therapy versus mastectomy: A multicenter study in Taiwan. Jpn. J. Clin. Oncol. 2017;47:909–918. doi: 10.1093/jjco/hyx099.
    1. Dorjgochoo T., Kallianpur A., Zheng Y., Gu K., Chen Z., Zheng W., Lu W., Shu X.O. Impact of menopausal symptoms on quality of life 6 months after systemic breast cancer treatment: Results from the Shanghai Breast Cancer Survival Study. Breast Cancer Res. Treat. 2010;119:725–735. doi: 10.1007/s10549-009-0434-x.
    1. Paskett E., Herndon J., 2nd, Donohue K., Naughton M., Grubbs S., Pavy M., Hensley M., Stark N., Kornblith A., Bittoni M., et al. Health-related quality of life in long-term breast cancer survivors: Differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. Cancer. 2009;115:1109–1120. doi: 10.1002/cncr.24140.
    1. Mortada E.M., Salem R.A., Elseifi O.S., Khalil O.M. Comparing Health-Related Quality of Life among Breast Cancer Patients Receiving Different Plans of Treatment. Egypt. J. Community Health. 2018;43:1183–1191. doi: 10.1007/s10900-018-0538-5.
    1. Calabrich A., Katz A. Management of anemia in cancer patients. Future Oncol. 2011;7:507–517. doi: 10.2217/fon.11.24.
    1. Schrijvers D., De Samblanx H., Roila F., ESMO Guidelines Working Group Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 2010;21:v244–v247. doi: 10.1093/annonc/mdq202.
    1. Bower J.E., Ganz P.A. Symptoms: Fatigue and Cognitive Dysfunction. Adv. Exp. Med. Biol. 2015;862:53–75.
    1. Deger M., Eisterer W., Kutikova L., Salek S. Hemoglobin level at initiation of darbepoetin alfa: Impact on need for transfusion and associatedcosts in chemotherapy-induced anemia treatment in Europe. Support Care Cancer. 2013;21:485–493. doi: 10.1007/s00520-012-1538-0.
    1. Tecza K., Pamula-Pilat J., Lanuszewska J., Butkiewicz D., Grzybowska E. Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018;9:9114–9136. doi: 10.18632/oncotarget.24148.
    1. Ozer H. The timing of chemotherapy-induced neutropenia and its clinical and economic impact. Oncology (Williston Park) 2006;20:11–15.
    1. Camp-Sorrell D. Chemotherapy toxicities and management. In: Yarbo C.H., Wujcik D., Gobel O.B.H., editors. Cancer Nursing. Principles and Practice. 7th ed. Jones & Barlett Publishers; Sudbury, MA, USA: 2011. pp. 458–500.
    1. Kaur N., Gupta A., Sharma A.K., Jain A. Survivorship issues as determinants of quality of life after breast cancer treatment: Report from a limited resource setting. Breast. 2018;41:120–126. doi: 10.1016/j.breast.2018.07.003.
    1. Fasoi-Barka G., Kelesi-Stauropoulou M., Kοutsopοulοu-Sofikiti V.E., Theodosopoulou E., Mpirmpas K., Katostaras T. Study for the change of healthrelated quality of life in women with early stage breast cancer, one year after the diagnosis. To Vima tou Asklipiou. 2010;9:76–99.
    1. Ware J.E., Jr., Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J. Clin. Epidemiol. 1998;51:903–912. doi: 10.1016/S0895-4356(98)00081-X.
    1. Arapakis G. Clinical Symptoms and Diagnostics, Medical Editions. Vasiliadis; Athens, Greece: 2012.
    1. Hoaglin D.C., Iglewicz B. Fine tuning some resistant rules for outlier labeling. J. Am. Stat. Assoc. 1987;82:1147–1149. doi: 10.1080/01621459.1987.10478551.
    1. Osborne J.W. Improving your data transformations: Applying the Box-Cox transformation. Pract. Assess. Res. Eval. 2010;15:1–9.
    1. Gold M., Dunn L.B., Phoenix B., Paul S.M., Hamolsky D., Levine J.D., Miaskowski C. Co-occurrence of anxiety and depressive symptoms following breast cancer surgery and its impact on quality of life. Eur. J. Oncol. Nurs. 2016;20:97–105. doi: 10.1016/j.ejon.2015.06.003.
    1. De Vos F.Y., van Laarhoven H.W., Laven J.S., Themmen A.P., Beex L.V., Sweep C.G., Seynaeve C., Jager A. Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline. Crit. Rev. Oncol. Hematol. 2012;84:252–260. doi: 10.1016/j.critrevonc.2012.06.005.
    1. Zainal N.Z., Nik-Jaafar N.R., Baharudin A., Sabki Z.A., Ng C.G. Prevalence of depression in breast cancer survivors: A systematic review of observational studies. Asian Pac. J. Cancer Prev. 2013;14:2649–2656. doi: 10.7314/APJCP.2013.14.4.2649.
    1. Marino J.L., Saunders C.M., Emery L.I., Green H., Doherty D.A., Hickey M. How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer? Menopause. 2016;23:1000–1008. doi: 10.1097/GME.0000000000000664.
    1. Yong C., Tsogzolmaa D., Ping-Ping B., Ying Z., Hui C., Wei L., Xiao-Ou S. Menopausal symptoms among breast cancer patients: A potential indicator of favorable prognosis. PLoS ONE. 2013;8:e75926.
    1. Ganz P.A., Petersen L., Bower J.E., Crespi C.M. Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months from the Mind-Body Study. J. Clin. Oncol. 2016;34:816–824. doi: 10.1200/JCO.2015.64.3866.
    1. Bardwell W.A., Ancoli-Israel S. Breast cancer and Fatigue. Sleep Med. Clin. 2008;3:61–71. doi: 10.1016/j.jsmc.2007.10.011.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren